With the continuous breakthroughs in molecular biology and biochemistry, we have constantly made great progress in the treatment of lung cancer. There is no doubt that standard treatment (such as surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy) has greatly improved the prognosis of lung cancer populations. In particular, the immunotherapy has brought more and more good news to countless lung cancer patients. In contrast to these standard treatments, traditional Chinese medicine (TCM) rarely has a profound and comprehensive overview in the field of lung cancer. This article will summarize the latest progress of TCM in lung cancer which is mainly non-small cell lung cancer (NSCLC) from theory to clinical practice, which would carry forward the sophisticated TCM and promote the development of modern medicine.

随着分子生物学和生物化学领域的不断突破，我们在肺癌治疗方面不断取得长足进步。毫无疑问，标准治疗（例如手术，放疗，化学疗法，靶向治疗和免疫治疗）已大大改善了肺癌人群的预后。尤其是，免疫疗法给无数肺癌患者带来了越来越多的好消息。与这些标准疗法相反，中药（TCM）在肺癌领域很少有深刻而全面的概述。本文将从理论到临床总结了肺癌中医药的最新进展，主要是非小细胞肺癌（NSCLC），这将推动中医药的发展，促进现代医学的发展。